JEFFREY KASSELMAN: Open Payments
NPI 1316005366 · RUSSELL, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$308 in 17 payments from 8 companies in 2025. Trend: 2023 $14 · 2024 $0 · 2025 $308
Food & beverage: $308
| Company | Payments | Amount |
|---|---|---|
| Sumitomo Pharma America, Inc. | 4 | $85 |
| Novartis Pharmaceuticals Corporation | 3 | $63 |
| AstraZeneca Pharmaceuticals LP | 3 | $45 |
| ABBVIE INC. | 2 | $32 |
| Electromed, Inc. | 2 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Insulet Corporation | 1 | $20 |
| Lilly USA, LLC | 1 | $14 |
Products named: GEMTESA, LEQVIO, FARXIGA, SMARTVEST, REXULTI, Omnipod, UBRELVY, QULIPTA.
Industry payments across KS — which companies pay providers there.
